非诺特罗
| 中文名称 | 非诺特罗 |
|---|---|
| 中文同义词 | 非诺特罗氢溴酸盐;非诺特罗;5-[1-羟基-2-[[2-(4-羟基苯基)-1-甲基乙基]氨基]乙基]-1,3-苯二酚;甲醇中非诺特罗标准溶液;非诺特罗检测标准品;甲醇中非诺特罗;甲醇中非诺特罗溶液标准物质 |
| 英文名称 | Fenoterol |
| 英文同义词 | 1-(p-hydroxyphenyl)-2-((beta-hydroxy-beta-(3’,5’-dihydroxyphenyl))ethyl)amin;1,3-benzenediol,5-(1-hydroxy-2-((2-(4-hydroxyphenyl)-1-methylethyl)amino)eth;3,5-dihydroxy-alpha-(((p-hydroxy-alpha-methylphenethyl)amino)methyl)benzyla;benzylalcohol,3,5-dihydroxy-alpha-(((p-hydroxy-alpha-methylphenethyl)amino)me;lcohol;opropane;1-(3,5-Dihydroxyphenyl)-1-hydroxy-2-[1-(4-hydroxyphenyl)isopropyl]aminoethane;1-(3,5-Dihydroxyphenyl)-2-(p-hydroxy-α-methylphenethylamino)ethanol |
| CAS号 | 13392-18-2 |
| 分子式 | C17H21NO4 |
| 分子量 | 303.35 |
| EINECS号 | 680-817-2 |
| 相关类别 | 瘦肉精类;平喘药物;对照品;API |
| Mol文件 | 13392-18-2.mol |
| 结构式 |  |
非诺特罗 性质
| 熔点 | 181-183°C |
|---|---|
| 沸点 | 566.0±45.0 °C(Predicted) |
| 密度 | 1.289±0.06 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 酸度系数(pKa) | pKa 8.5 (Uncertain);10.0 (Uncertain) |
| 形态 | 固体 |
| 颜色 | 浅棕色至棕色 |
| CAS 数据库 | 13392-18-2(CAS DataBase Reference) |
Fenoterol (Phenoterol) 是β2 adrenoreceptor激动剂，具有支气管扩张活性。
| Target | Value |
|
β2 adrenoreceptor
() |
Fenoterol (1 μM; pre-incubated 30 minutes) treatment reduces AICAR-induced AMPK activation, NF-κB activation and TNF-α release, and also significantly downregulates the elevated phosphorylation levels of AMPK.
Fenoterol inhibits lipopolysaccharide (LPS)-induced AMPK activation and inflammatory cytokine production in THP-1 cells.
Fenoterol is also a potent exosome biogenesis and/or secretion activator in PC cells.
Western Blot Analysis
| Cell Line: | THP-1 cells stimulated with AICAR |
| Concentration: | 1 μM |
| Incubation Time: | Pre-incubated 30 minutes |
| Result: | Significantly downregulated the elevated phosphorylation levels of AMPK. |
Fenoterol (0.7 mg/kg; intraperitoneal injection; twice a day; for 3 weeks) treatment suppresses mechanical allodynia during chronic treatment.
| Animal Model: | Male C57BL/6J mice (6 weeks old) with neuropathy |
| Dosage: | 0.7 mg/kg |
| Administration: | Intraperitoneal injection; twice a day; for 3 weeks |
| Result: | Alleviated neuropathic allodynia during chronic treatment. |